Related Experiment Video
Updated: Sep 14, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Comparative transcriptome and proteome analysis explores the antitumor key regulators of ergosterone in H22
1College of Chinese Materia Medica & Key Research Laboratory for the Development and Utilization of Fungi Traditional Chinese Medicine Resources, Jilin Agricultural University, Changchun, 130118, China; Key Laboratory of Edible Fungi Resources and Utilization, Ministry of Agriculture and Rural Affairs, Jilin Agricultural University, Changchun, Jilin, 130118, China.
Abstract:
Ergosterone has been proved to have potential antitumor effect on H22 tumor-bearing mice, but the antitumor mechanism and key regulators are still unclear. The current study was aimed to explore the key regulators responsible for antitumor of ergosterone using whole transcriptome and proteome analysis in H22 tumor-bearing mice model. The model of H22 tumor-bearing mice was constructed according to the histopathological data and biochemical parameters. The isolated tumor tissues of different treatment groups were subjected to transcriptomic and proteomic analysis. Our findings demonstrated that 472 differentially expressed genes and 658 proteins were identified in the tumor tissue of different treatment groups through RNA-Seq and liquid chromatography with tandem mass spectrometry-based proteomic analysis, respectively. The combined omics analysis revealed three critical genes/proteins, including Lars2, Sirpα and Hcls1 that could play a role in antitumor pathways. Furthermore, Lars2, Sirpα and Hcls1 genes/proteins, as key regulators of the antitumor effect of ergosterone, were verified by qRT-PCR and western blotting methods, respectively. In summary, our study provides new insights into analysing the antitumor mechanism of ergosterone from the point of view of gene and protein expression and will encourage further development of the antitumor pharmaceutical industry.
Insights
Ergosterone shows antitumor effects by regulating key genes and proteins like Lars2, Sirpα, and Hcls1 in mice. This study clarifies ergosterone
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Ergosterone exhibits potential antitumor activity against H22 tumors in mice.
- The precise antitumor mechanisms and regulatory pathways remain largely unelucidated.
Purpose of the Study:
- To investigate the key molecular regulators underlying ergosterone's antitumor effects.
- To utilize integrated transcriptomic and proteomic analyses in a H22 tumor-bearing mouse model.
Main Methods:
- Construction of a H22 tumor-bearing mice model.
- Transcriptomic analysis using RNA-Seq.
- Proteomic analysis via liquid chromatography-tandem mass spectrometry (LC-MS/MS).
- Validation using quantitative real-time PCR (qRT-PCR) and Western blotting.
Main Results:
- Identification of 472 differentially expressed genes and 658 proteins in tumor tissues.
- Combined omics analysis pinpointed Lars2, Sirpα, and Hcls1 as critical regulators.
- Experimental validation confirmed the roles of Lars2, Sirpα, and Hcls1 in ergosterone's antitumor action.
Conclusions:
- Lars2, Sirpα, and Hcls1 are identified as key regulators of ergosterone's antitumor efficacy.
- This study provides novel insights into ergosterone's antitumor mechanisms at the gene and protein expression levels.
- Findings may support the development of ergosterone-based cancer therapies.
